SQZ Biotech features a cell engineering technology designed to deliver a diverse set of materials into patient cells.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 21, 2022 | Grant | $2M | 1 | National Institute of General Medical Science | — | Detail |
Feb 12, 2021 | Post-IPO Equity | $60M | — | — | — | Detail |
Oct 29, 2020 | IPO | $81.17M | — | — | — | Detail |
May 18, 2020 | Series D | $65M | 7 | Temasek Holdings | — | Detail |
Dec 18, 2019 | Series D | — | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institute of General Medical Science | Yes | Grant |
Temasek Holdings | Yes | Series D |
National Science Foundation | Yes | Grant |
GV | — | Series D |
Illumina Ventures | — | Series D |
Invus | — | Series D |
JDRF T1D Fund | — | Series D |
NanoDimension | — | Series D |
Polaris Partners | — | Series D |
Alumni Ventures | — | Series D |